z-logo
Premium
Superiority of occipital donor sites for split‐thickness skin grafting in dermatosurgery: Results of a prospective randomized controlled study
Author(s) -
Kovacs Maximilian,
Karsai Syrus,
Podda Maurizio
Publication year - 2017
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/ddg.13337
Subject(s) - medicine , occiput , randomized controlled trial , surgery , thigh , skin grafting , prospective cohort study
Summary Background Split‐thickness skin grafts are commonly used in dermatosurgery. For occipital donor sites, retrospective studies have shown good results with respect to graft take and healing rates. Nevertheless, the majority of grafts in dermatosurgery are harvested from the thigh. To date, there has been no prospective randomized controlled study comparing occipital versus femoral donor sites. Patients and methods Following micrographically controlled R0 tumor resection, 108 patients were randomized prior to undergoing split‐thickness skin grafting (donor site: occiput vs. thigh). Follow‐up examinations were carried out on day 3, 5, 7, and 14, as well as one month and three months after surgery. Documented data included graft take rates, re‐epithelialization rates at the donor site, pain, cosmetic outcome, Vancouver Scar Scale (VSS), and complications. Results Occipital donor sites showed significantly faster reepithelization, less pain, fewer complications, a better cosmetic outcome, and better results on the VSS. With regard to graft take rates, grafts harvested from the occiput were significantly superior on days 3 and 5. Conclusions This is the first randomized controlled trial showing a significant superiority of occipital compared to femoral donor sites regarding re‐epithelialization, pain, cosmetic outcome and the Vancouver Scar Scale.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here